Full-Time
Precision engineering for health and safety
$158.6k - $237.8k/yr
Northbrook, IL, USA
In Person
Bachelor's, MBA
See people who can refer or advise you
IDEX manufactures high-precision components and systems for specialized industries, including medical diagnostics, fire safety, and industrial manufacturing. Its products, such as liquid subassemblies for labs and pumps for fire trucks, work by providing exact control and measurement in environments where accuracy is critical to safety or research. Unlike competitors that focus on mass-market goods, IDEX specializes in niche markets by engineering custom solutions for highly technical problems. The company's goal is to provide reliable, engineered tools that help professionals in health, rescue, and industry perform essential tasks more effectively.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Northbrook, Illinois
Founded
1987
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
IDEX reported Q2 revenues of $920.6 million, up 6.4% year-on-year and exceeding analyst expectations by 1.7%. The company delivered a strong quarter with full-year EPS guidance surpassing forecasts and beating EBITDA estimates. IDEX achieved the highest guidance raise among gas and liquid handling stocks tracked. The stock rose 4.3% following the earnings announcement and currently trades at $234.37. The gas and liquid handling sector showed strength overall in Q2, with 11 tracked companies beating revenue consensus estimates by 2.1% on average. However, next quarter's guidance came in 0.8% below expectations. SPX Technologies led the group with revenues of $679 million, up 22.9% year-on-year, outperforming expectations by 5.8%. The stock gained 4.2% after reporting.
IDEX Corporation reported strong second quarter 2026 results, exceeding expectations with organic sales growth of 5% and adjusted earnings per share of $2.32, up 12% year-over-year. Adjusted EBITDA margin expanded 70 basis points to 28.1%. The company's performance was driven by higher volumes from growth platforms and strong operational execution. Results were modestly impacted by IEEPA tariff refunds, which slightly reduced organic growth whilst providing minor favourability to margins and earnings. President and Chief Executive Officer Eric Ashleman noted the results continued momentum established earlier in the year. The earnings call featured remarks from Ashleman and Chief Financial Officer Sean Gillen, who provided additional financial details and an updated outlook for 2026.
Idex reported Q2 2026 revenue of $920.6 million, up 6.4% year-over-year, beating the consensus estimate of $902.43 million by 2.01%. EPS came in at $2.32, compared to $2.07 in the prior-year quarter, exceeding the $2.10 estimate by 10.48%. The Health & Science Technologies segment led growth with $415 million in revenue, up 13.6% year-over-year and above the $406.67 million estimate. Fluid & Metering Technologies generated $317.1 million, whilst Fire & Safety/Diversified Products posted $189.9 million. Organic sales growth reached 5%, surpassing the 3.4% analyst estimate. Idex shares have declined 1% over the past month, compared to a 1.9% gain for the S&P 500.
Myrias Optics appoints Neil Anderson as chief revenue officer to drive global growth. July 22, 2026 Neil Anderson, Ph.D Myrias Optics has named Neil Anderson, Ph.D., as chief revenue officer, strengthening its executive leadership team as the company expands commercialization of its wafer-level metaoptics and diffractive optical technologies. Anderson will lead Myrias' global commercial strategy, overseeing sales, business development, marketing, strategic partnerships and commercial operations. The appointment comes as demand for advanced optical components accelerates across industries including artificial intelligence infrastructure, augmented and virtual reality, consumer electronics and advanced imaging. Myrias is positioning its proprietary nanoimprint manufacturing platform as a scalable approach to producing wafer-level flat optics for high-volume applications, an area gaining momentum as manufacturers seek more compact and cost-effective optical technologies. In his new role, Anderson will focus on expanding global adoption of Myrias' manufacturing platform while supporting commercialization across key growth markets, including AI data centers, consumer electronics, industrial photonics, life sciences and advanced imaging. The company believes its wafer-level production approach can help address growing demand for next-generation optical components as AI computing, immersive technologies and photonics applications continue to evolve. Anderson brings more than 15 years of commercial leadership experience in the optics and photonics industry, where he has helped bring advanced technologies from development to large-scale commercial deployment. His background spans strategic business development, go-to-market execution, customer engagement and operational leadership across global technology markets. Before joining Myrias, Anderson held senior executive roles at Gooch & Housego, quantum technology company Infleqtion and IDEX Corporation. During his career, he led global commercial organizations, developed growth strategies and built long-term partnerships with technology companies and Fortune 1000 customers. His experience covers optical components, integrated photonics, imaging technologies, photonic subsystems and advanced manufacturing serving semiconductor, data communications, aerospace and defense, medical diagnostics, life sciences, industrial sensing, quantum computing and consumer electronics markets. Chief Executive Officer John Fijol said Anderson's combination of commercial leadership and industry expertise will support Myrias' next phase of growth as it scales manufacturing and expands customer adoption worldwide. He said Anderson's experience commercializing advanced optics technologies and building enterprise partnerships will be important as the company moves from technology development toward broader market deployment. Anderson said he was attracted by Myrias' manufacturing platform and its potential to reshape production of AR waveguides and metaoptics at scale. He said the technology creates opportunities to support customers developing next-generation products in competitive global markets while accelerating adoption of flat optics across a range of emerging applications. Holding a doctorate in optical science and engineering from the Institute of Optics in Rochester, New York, along with a master's degree in physics, Anderson combines technical expertise with commercial leadership. His ability to bridge scientific research and business execution has helped companies transform advanced photonics technologies into commercially viable products and scalable businesses. The executive appointment reflects broader momentum across the optics and photonics sector, where advances in AI infrastructure, spatial computing and precision sensing are driving increased demand for high-performance optical components that can be manufactured efficiently at scale. By strengthening its commercial leadership, Myrias Optics is positioning itself to capitalize on growing interest in wafer-level optical technologies as customers seek manufacturing solutions capable of supporting next-generation devices across multiple high-growth industries.
IDEX Corporation, a diversified industrial company with a $16.6 billion market cap, has seen shares fall 1.5% from its 52-week high of $228.26, though the stock has gained 26.4% year-to-date, outperforming the State Street Industrial Select Sector SPDR ETF's 16.6% rise. The company operates through three segments serving healthcare, life sciences, fluid handling and fire safety industries. Shares jumped 5.8% on 29 April after reporting stronger-than-expected first-quarter results, with sales rising 9% year-over-year to $887 million and adjusted earnings per share increasing 14% to $2. IDEX raised its full-year guidance, projecting organic sales growth of 3% to 4% and adjusted earnings per share of $8.35 to $8.55. The stock has returned 28.5% over the past 52 weeks.